Leland Gershell
Stock Analyst at Oppenheimer
(4.22)
# 424
Out of 4,876 analysts
133
Total ratings
37.7%
Success rate
22.51%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $11.10 | +98.20% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $173.91 | +28.81% | 11 | Jun 13, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $10 | $1.24 | +706.45% | 1 | Jun 6, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $36 → $10 | $13.50 | -25.93% | 10 | Jun 3, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $4.66 | +50.21% | 2 | May 9, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $704 → $708 | $561.20 | +26.16% | 7 | May 9, 2025 | |
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.53 | +553.59% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $5.69 | +251.49% | 3 | Mar 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $54.93 | +78.41% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $61.42 | +23.74% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $18.00 | +188.89% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $114.77 | +28.08% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.62 | +702.44% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.73 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $83.84 | -12.93% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.98 | +231.66% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $44.65 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.65 | +721.92% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.78 | +575.71% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.09 | +28,868.71% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $14.54 | +92.57% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $2.88 | +768.06% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $30.36 | +140.49% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $1.56 | +1,182.05% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.85 | +32.72% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.70 | +644.68% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.78 | +1,189.49% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.43 | +1,298.60% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $319.80 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.93 | +573.58% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $1.98 | +5,960.61% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.80 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.44 | +80,989,776.27% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $16.69 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.25 | +3,900.00% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $15.89 | - | 5 | Mar 31, 2020 |
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $11.10
Upside: +98.20%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $173.91
Upside: +28.81%
Climb Bio
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.24
Upside: +706.45%
UroGen Pharma
Jun 3, 2025
Maintains: Outperform
Price Target: $36 → $10
Current: $13.50
Upside: -25.93%
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $4.66
Upside: +50.21%
argenx SE
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $561.20
Upside: +26.16%
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.53
Upside: +553.59%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $5.69
Upside: +251.49%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $54.93
Upside: +78.41%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $61.42
Upside: +23.74%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $18.00
Upside: +188.89%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $114.77
Upside: +28.08%
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.62
Upside: +702.44%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.73
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $83.84
Upside: -12.93%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.98
Upside: +231.66%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $44.65
Upside: -
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.65
Upside: +721.92%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.78
Upside: +575.71%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.09
Upside: +28,868.71%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $14.54
Upside: +92.57%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $2.88
Upside: +768.06%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $30.36
Upside: +140.49%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $1.56
Upside: +1,182.05%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.85
Upside: +32.72%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.70
Upside: +644.68%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.78
Upside: +1,189.49%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.43
Upside: +1,298.60%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $319.80
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.93
Upside: +573.58%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $1.98
Upside: +5,960.61%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.80
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.44
Upside: +80,989,776.27%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $16.69
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.25
Upside: +3,900.00%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $15.89
Upside: -